Manufacturer
16 recalls in our database name Par Pharmaceutical, Inc. as the manufacturing or recalling firm.
Of the 16 recalls from Par Pharmaceutical, Inc. we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 4 (25%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Par Pharmaceutical Inc. is recalling 11,347 bottles of BusPIRone Hydrochloride Tablets 7.5 mg because they failed impurity and degradation specifications.
Par Pharmaceutical is recalling 29,352 bottles of Glycopyrrolate Tablets, USP 1 mg, because an unknown impurity was detected.
Par Pharmaceutical Inc. is recalling 13,008 bottles of Prednisone Tablets USP 5 mg because an incorrect expiration date was identified on the product.
Par Pharmaceutical is recalling 9,936 cartons of Frovatriptan Succinate Tablets, 2.5mg, because they are labeled with an incorrect expiration date.
Par Pharmaceutical is recalling Mycophenolate Mofetil for Injection due to the presence of particulate matter and a glass fragment in one vial.
Par Pharmaceutical is recalling Pramipexole dihydrochloride extended release tablets because they contain a known impurity at levels exceeding specifications.
Par Pharmaceutical is recalling specific lots of Travoprost Ophthalmic Solution because the dropper tips may be damaged, compromising sterility.
Par Pharmaceutical is recalling Gildess 24 FE 1.5/30 oral contraceptives because the ethinyl estradiol component is subpotent. The recall covers 44,127 tablets distributed nationwide and in Puerto Rico.
Par Pharmaceutical is recalling Gildess 1/20 tablets because they contain subpotent levels of ethinyl estradiol. The recall covers 393,981 tablets distributed nationwide and in Puerto Rico.
Par Pharmaceutical is recalling Gildess 1.5/30 tablets because they contain subpotent levels of ethinyl estradiol. The recall covers specific lots distributed nationwide and in Puerto Rico.
Par Pharmaceutical is recalling Gildess FE 1/20 tablets because the ethinyl estradiol component is subpotent. The recall covers 822,009 tablets distributed nationwide and in Puerto Rico.
Par Pharmaceutical is recalling Gildess FE 1.5/30 tablets because they may contain subpotent levels of ethinyl estradiol.
Par Pharmaceutical is recalling Meclizine Hydrochloride Tablets because they failed impurity specifications. The recall covers 100 and 1000-count bottles distributed nationwide.
Par Pharmaceutical is recalling specific lots of Meclizine Hydrochloride 12.5 mg tablets because they failed impurity specifications.
Par Pharmaceutical Inc. is recalling Mafenide Acetate 5% Topical Solution packets due to the presence of oxidized steel, organic material, and shredded polypropylene.
Par Pharmaceutical is recalling one lot of HydrALAZINE Hydrochloride tablets because small aluminum particles were found in the product.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
Par Pharmaceutical
Source: Wikidata (Q7133598), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.